Press Releases

November 22, 2023

Regulatory

Nomination Committee appointed ahead of AGM 2024 in SynAct Pharma AB

November 14, 2023

Non Regulatory

SynAct Pharma comments on ownership changes in Bioinvest Aps

November 1, 2023

Regulatory

SynAct Pharma announces evaluation of the 4-week RESOLVE P2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate

October 31, 2023

Regulatory

Change in number of shares and votes in SynAct Pharma

October 24, 2023

Regulatory

SynAct Pharma publishes Q3 2023 interim report

October 12, 2023

Regulatory

SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm

October 11, 2023

Regulatory

SynAct Pharma AB carries out a directed issue of shares and warrants raising initial gross proceeds of SEK 60.5 million

October 9, 2023

Non Regulatory

Invitation to SynAct’s interim report Q3 2023 presentation

October 3, 2023

Non Regulatory

SynAct Pharma announces additional data from the EXPAND P2b clinical trial further supporting efficacy and activity seen in patients with elevated CRP

September 12, 2023

Regulatory

SynAct Pharma announces additional data from the EXPAND P2b clinical trial and identifies population with responsiveness to resomelagon

September 4, 2023

Regulatory

SynAct Pharma announces top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients

August 17, 2023

Non Regulatory

SynAct Pharma completes dosing in part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)

August 4, 2023

Regulatory

SynAct Pharma publishes Q2 2023 interim report

July 21, 2023

Non Regulatory

Invitation to SynAct Pharma’s interim report Q2 2023 presentation

July 20, 2023

Non Regulatory

SynAct Pharma completes patient recruitment for part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)

July 14, 2023

Non Regulatory

SynAct Pharma announces the completion of dosing in the Phase 2b EXPAND study of resomelagon (AP1189) in early severe rheumatoid arthritis patients

June 29, 2023

Non Regulatory

SynAct Pharma to present at 19th World Congress of Basic and Clinical Pharmacology in Glasgow on July 4

May 31, 2023

Non Regulatory

SynAct Pharma to present at the 2023 BIO International Convention

May 29, 2023

Non Regulatory

SynAct Pharma to participate at ABGSC Life Science Summit May 30

May 25, 2023

Regulatory

Bulletin from the annual general meeting in SynAct Pharma AB on May 25, 2023

May 15, 2023

Regulatory

SynAct Pharma appoints Björn Westberg as CFO

May 5, 2023

Regulatory

SynAct Pharma publishes Q1 2023 interim report

April 24, 2023

Regulatory

SynAct Pharma completes patient recruitment for Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis

April 17, 2023

Non Regulatory

SynAct Pharma announces program for the upcoming Capital Markets Day in Stockholm on May 5, 2023

April 13, 2023

Regulatory

Notice of annual general meeting in SynAct Pharma AB

April 13, 2023

Regulatory

SynAct Pharma publishes Annual Report 2022

April 3, 2023

Regulatory

The Nomination Committee of SynAct Pharma proposes Uli Hacksell as new Chairman and Thomas von Koch as new Board member

April 3, 2023

Regulatory

SynAct Pharma appoints Torbjørn Bjerke as new CEO

March 30, 2023

Non Regulatory

SynAct Pharma introduces resomelagon as generic name for AP1189

March 28, 2023

Non Regulatory

SynAct Pharma to host a Capital Markets Day in Stockholm on May 5, 2023

March 23, 2023

Non Regulatory

SynAct strengthens its patent portfolio

February 17, 2023

Regulatory

SynAct Pharma publishes Annual Results for 2022

February 1, 2023

Regulatory

Patrik Renblad is leaving SynAct Pharma and the search for a new CFO has been initiated

January 31, 2023

Regulatory

Change in number of shares and votes in SynAct Pharma

January 16, 2023

Regulatory

SynAct Pharma completes the acquisition of TXP Pharma

January 12, 2023

Regulatory

Bulletin from the extraordinary general meeting of SynAct Pharma AB